May Awareness Month will be kicked-off with updates from Michael Hayden, Andrew Feigin, Ralf Reilman and Anne Rosser about the Phase 3 trial where the drug Pridopidine is tested on HD patients. Close to 500 participants in North America and Europe are given either the active drug or placebo for more than one year.
The recruitment went fast and smooth and we can expect to have the first results published sometime first half of 2023. The speakers will tell us about the background and mechanisms of Pridopidine, status for the trial and potential next steps. What will happen if the trial demonstrates effect? What if it doesn’t?
Join us to learn more and discuss with the lead management of the trial! Dina de Sousa from EHA will take part in a panel discussion together with the speakers.